Answers are grounded in this paper and cite their sources.
Should DTG + 3TC demonstrate high rates of virologic suppression, this regimen will be cost-effective and would save >$500 million in ART costs in the United States over 5 years.
No takes yet. Share an insight, caveat, or question.
Girouard et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: